Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 2/20 | 0.46 |
| ▸ | ECE1 | P42892 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118069 | 0.97 | C5AR1 (0.52) | C5AR1MC4R | |
| SCHEMBL29666221 | 0.97 | C5AR1 (0.52) | C5AR1MC4R | |
| SCHEMBL29666297 | 0.95 | C5AR1 (0.52) | C5AR1MC4R | |
| SCHEMBL30093002 | 0.94 | C5AR1 (0.55) | C5AR1ACEERAP2CTSLCTSS | |
| SCHEMBL31257022 | 0.94 | C5AR1 (0.49) | C5AR1ACECTSLCTSSCTSK | |
| SCHEMBL31091329 | 0.94 | GHSR (0.48) | C5AR1ACECTSLCTSSCTSK | |
| SCHEMBL29754547 | 0.94 | C5AR1 (0.55) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL30518049 | 0.92 | C5AR1 (0.53) | C5AR1CTSLCTSSCTSKCTSH | |
| SCHEMBL31555133 | 0.92 | MC4R (0.52) | C5AR1MC4R | |
| SCHEMBL29419493 | 0.92 | MC4R (0.52) | C5AR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | C5AR1 760/4885ACE 1921/4885ERAP2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.